Interluekin-6 inhibitors for the treatment of adult-onset Still's disease

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Adult-onset Still's disease is a systemic inflammatory disease characterized by high spiking fever, arthritis, evanescent skin rash, leukocytosis, and hyperferritinemia. The pathogenesis of adult-onset Still's disease has not been fully understood yet; however, multiple proinflammatory cytokines, such as IL-1β and IL-6, play important roles in the development of adult-onset Still's disease. IL-6 is a multifunctional cytokine that accelerates the differentiation of macrophages and cytotoxic T-cells and chemotaxis of neutrophils and macrophages. Serum concentrations of IL-6 well correlate with disease activity of adult-onset Still's disease, and blockade of IL-6 has been proven to be effective in active adult-onset Still's disease. This review will focus on the recent understanding of the role of proinflammatory cytokines of adult-onset Still's disease and the efficacy of IL-6 inhibitors for the treatment of adult-onset Still's disease.

Original languageEnglish
Pages (from-to)12-15
Number of pages4
JournalModern rheumatology
Issue number1
Publication statusPublished - 2022 Jan 1


  • Interluekin-6
  • adult-onset Still's disease
  • tocilizumab

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Interluekin-6 inhibitors for the treatment of adult-onset Still's disease'. Together they form a unique fingerprint.

Cite this